PE20121282A1 - Antagonistas de espiro-oxindol de mdm2 - Google Patents

Antagonistas de espiro-oxindol de mdm2

Info

Publication number
PE20121282A1
PE20121282A1 PE2012000616A PE2012000616A PE20121282A1 PE 20121282 A1 PE20121282 A1 PE 20121282A1 PE 2012000616 A PE2012000616 A PE 2012000616A PE 2012000616 A PE2012000616 A PE 2012000616A PE 20121282 A1 PE20121282 A1 PE 20121282A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
oxindol
mdm2
spiro
Prior art date
Application number
PE2012000616A
Other languages
English (en)
Inventor
Shaomeng Wang
Shanghai Yu
Wei Sun
Sanjeev Kumar
Duxin Sun
Peng Zou
Yujun Zhao
Donna Mceachern
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43974649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121282(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Michigan filed Critical Univ Michigan
Publication of PE20121282A1 publication Critical patent/PE20121282A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE ESPIRO-OXINDOL DE FORMULA (I) DONDE R1a, R1b, R1c Y R1d SON CADA UNO H, HALOGENO, HIDROXI, AMINO, NITRO, CN, ENTRE OTROS; R2 ES ARILO O HETEROARILO OPCIONALMENTE SUSTITUIDOS; R3 ES ALQULO, (CICLOALQUIL)ALQUILO, CICLOALQUILO OPCIONALMENTE SUSTITUIDOS, ENTRE OTROS; R4 ES H O ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO; R5 ES EL COMPUESTO DE FORMULA (R5-1), ENTRE OTROS, EN DONDE R6a Y R6b SON CADA UNO H O ALQUILO(C1-C6); R7 ES H, ALQUILO(C1-C6) O CICLOALQUILO; R8a Y R8b SON CADA UNO H, ALQUILO(C1-C6), CICLOALQUILO, ENTRE OTROS; W1 ES -OR9a, ENTRE OTROS; W2 ES -OR10, ENTRE OTROS, EN DONDE R9a Y R10 SON CADA UNO H; X ES O, S O NR'; Y ES O, S O NR'', DONDE R' Y R'' SON CADA UNO H, ALQUILO, ARALQUILO O CICLOALQUILO OPCIONALMENTE SUSTITUIDOS. SON COMPUESTOS PREFERIDOS LOS DE FORMULA (i), (ii), ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA INTERACCION ENTRE p53 Y MDM2 SIENDO UTILES EN EL TRATAMIENTO DEL CANCER
PE2012000616A 2009-11-12 2010-11-10 Antagonistas de espiro-oxindol de mdm2 PE20121282A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26068509P 2009-11-12 2009-11-12
US26366209P 2009-11-23 2009-11-23

Publications (1)

Publication Number Publication Date
PE20121282A1 true PE20121282A1 (es) 2012-10-12

Family

ID=43974649

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000616A PE20121282A1 (es) 2009-11-12 2010-11-10 Antagonistas de espiro-oxindol de mdm2

Country Status (28)

Country Link
US (3) US8518984B2 (es)
EP (1) EP2499145B1 (es)
JP (1) JP2013510860A (es)
KR (1) KR20120099462A (es)
CN (2) CN102712650B (es)
AR (1) AR079026A1 (es)
AU (1) AU2010319595B2 (es)
BR (1) BR112012011317A2 (es)
CA (1) CA2780547C (es)
CL (1) CL2012001250A1 (es)
CO (1) CO6501131A2 (es)
CR (1) CR20120313A (es)
DO (1) DOP2012000131A (es)
EC (1) ECSP12011943A (es)
GT (1) GT201200147A (es)
IL (1) IL219706A (es)
MA (1) MA33815B1 (es)
MX (1) MX2012005507A (es)
NI (1) NI201200083A (es)
NZ (1) NZ600430A (es)
PE (1) PE20121282A1 (es)
RU (1) RU2553269C2 (es)
TN (1) TN2012000161A1 (es)
TW (1) TWI508967B (es)
UA (1) UA107814C2 (es)
UY (1) UY33029A (es)
WO (1) WO2011060049A2 (es)
ZA (1) ZA201203323B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2118123E (pt) 2007-01-31 2016-02-10 Harvard College Péptidos de p53 estabilizados e suas utilizações
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
UA107814C2 (uk) 2009-11-12 2015-02-25 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Спірооксіндольні антагоністи мdм2
US8088815B2 (en) * 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
RU2012147597A (ru) * 2010-04-09 2014-05-20 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Биомаркеры для ингибиторов mdm2, использующиеся для лечения заболевания
PT2603600T (pt) 2010-08-13 2019-02-27 Aileron Therapeutics Inc Macrociclos peptidomiméticos
EP2638046A4 (en) * 2010-11-12 2014-06-25 Univ Michigan SPIRO-OXINDOLES ANTAGONISTS OF MDM2
JP5792279B2 (ja) 2011-03-10 2015-10-07 第一三共株式会社 ジスピロピロリジン誘導体
BR112013028983A2 (pt) 2011-05-11 2017-02-07 Sanofi Sa antagonistas mdm2 espiro-oxindol
CA2852468A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
US9937178B2 (en) 2011-12-07 2018-04-10 Duke University Methods of identifying and using MDM2 inhibitors
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
RU2017145921A (ru) 2012-02-15 2019-02-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
CN103739566B (zh) * 2014-01-24 2016-01-20 中国人民解放军第三军医大学 含有磺酰胺的手性五元并环骨架化合物及制备方法和用途
ES2712973T3 (es) * 2014-04-17 2019-05-17 Univ Michigan Regents Inhibidores de MDM2 y métodos terapéuticos que usan los mismos
CN103992334A (zh) * 2014-05-29 2014-08-20 中国人民解放军第二军医大学 吲哚酮螺四氢硫代吡喃类抗肿瘤衍生物及其制备方法
EP3164401B1 (en) 2014-07-03 2018-12-26 Boehringer Ingelheim International GmbH New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
ES2959097T3 (es) * 2014-08-18 2024-02-20 Hudson Biopharma Inc Espiropirrolidinas como inhibidores de MDM2
JP6408318B2 (ja) * 2014-09-19 2018-10-17 日本テルペン化学株式会社 抗菌活性を持つ化合物、およびその製造方法
JP6412753B2 (ja) * 2014-09-19 2018-10-24 日本テルペン化学株式会社 抗菌活性を持つ化合物、およびその製造方法
CN112972378A (zh) 2014-09-24 2021-06-18 艾瑞朗医疗公司 拟肽大环化合物及其制剂
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
WO2016147205A1 (en) * 2015-03-13 2016-09-22 Council Of Scientific & Industrial Research Novel substituted 3-spirophosphoryl pyrazole-2-oxindoles as anti-infectives and process for the synthesis thereof
BR112017019738A2 (pt) 2015-03-20 2018-05-29 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
US9962380B2 (en) 2015-09-23 2018-05-08 Wisconsin Alumni Research Foundation Methods for treating cognitive deficits associated with fragile X syndrome
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
MX2018004207A (es) * 2015-10-09 2018-07-06 Boehringer Ingelheim Int Nuevos compuestos de espiro[3h-indol-3,2â´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53.
JP7001614B2 (ja) 2016-04-06 2022-02-03 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン リガンド依存性の標的タンパク質分解のための単官能性中間体
EP3440066B1 (en) 2016-04-06 2022-11-30 The Regents of The University of Michigan Mdm2 protein degraders
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
US9822128B1 (en) 2017-06-01 2017-11-21 King Saud University Substituted spirooxindoles
CN107312115B (zh) * 2017-06-22 2020-06-12 北京理工大学 一种双吲哚稀土金属催化剂、制备方法及应用
CN109988070B (zh) * 2017-12-29 2022-07-26 南京富润凯德生物医药有限公司 反式-1-羟基-1-(三氟甲基)-3-氨基环丁烷盐酸盐的中间体及制备方法和应用
KR101857408B1 (ko) * 2018-02-28 2018-05-14 경북대학교 산학협력단 탈모 예방 또는 치료용 조성물
MX2021003999A (es) 2018-10-08 2021-06-23 Univ Michigan Regents Moleculas de bajo peso molecular degradadoras de la proteina mdm2.
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
BR112022018678A2 (pt) 2020-03-19 2022-11-01 Kymera Therapeutics Inc Degradadores de mdm2 e usos dos mesmos
US20230313313A1 (en) 2020-08-27 2023-10-05 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using mdm2 antagonists
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
WO2022226426A1 (en) * 2021-04-24 2022-10-27 Universal Sequencing Technology Corporation A nanotrain for single-molecule detection
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2023086400A1 (en) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
WO2023086352A1 (en) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11858945B2 (en) 2021-11-12 2024-01-02 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
US20230295175A1 (en) * 2022-03-18 2023-09-21 Enanta Pharmaceuticals, Inc. Processes for the preparation of substituted spirooxindole derivatives
US11944604B1 (en) 2023-03-10 2024-04-02 King Saud University Nanoformulation of spriooxindole and methods for treating hepatocellular carcinoma

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219661A (en) 1962-12-14 1965-11-23 Warner Lambert Pharmaceutical Spirooxindole and spirodehydroindole alkaloids and process therefor
GB1056537A (en) 1963-07-16 1967-01-25 Smith Kline French Lab Improvements in or relating to crystalline alkaloids of mitragyna citiata and compositions thereof
JPS444986Y1 (es) 1966-10-20 1969-02-24
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
JPH044986A (ja) 1990-04-20 1992-01-09 Nippon Stainless Steel Co Ltd ニッケル・ステンレス鋼クラッド材の製造方法
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
RU2084449C1 (ru) 1994-03-02 1997-07-20 Всероссийский научный центр по безопасности биологически активных веществ 1-бензил-2-оксотриптамин гидрохлорид и его производные, обладающие гепатозащитной активностью
US5773455A (en) 1996-06-28 1998-06-30 Biomeasure, Incorporated Inhibitors of prenyl transferases
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
DE59814452D1 (de) 1997-01-20 2010-06-24 Immodal Pharmaka Gmbh Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung
US6114540A (en) 1997-09-08 2000-09-05 Arqule, Inc. Spiro[pyrrolidine-2,3'-oxindole] compounds and methods of use
ATE418730T1 (de) 1998-08-20 2009-01-15 Chugai Pharmaceutical Co Ltd Verfahren zum screenen von potenziellen verbindungen für das auffinden von einem anti- tumor-arzneistoff
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6831155B2 (en) 1999-12-08 2004-12-14 President And Fellows Of Harvard College Inhibition of p53 degradation
CN1182083C (zh) 2001-10-08 2004-12-29 廖宜芳 一种杀虫灭菌的配位肥及其制造方法
PL370909A1 (en) 2001-12-18 2005-05-30 F.Hoffmann-La Roche Ag Cis-imidazolines as mdm2 inhibitors
MXPA04005906A (es) 2001-12-18 2004-09-13 Hoffmann La Roche Cis-2,4,5-trifenil-.imidazolinas y uso de la misma para tratamiento de tumores.
JP4023184B2 (ja) 2002-03-11 2007-12-19 昭和電工株式会社 発光体粒子及びその製造方法並びにその用途
WO2003106384A2 (en) 2002-06-01 2003-12-24 Johns Hopkins University Novel boronic chalcone derivatives and uses thereof
AU2003291269A1 (en) 2002-11-08 2004-06-03 Irm Llc Methods and compositions for modulating p53 transcription factor
US20050227932A1 (en) 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
US7498336B2 (en) 2003-02-13 2009-03-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Deazaflavin compounds and methods of use thereof
US6916833B2 (en) 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
NZ601772A (en) 2003-07-29 2012-10-26 Signature R & D Holdings Llc Amino Acid Prodrugs
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
WO2005063774A1 (en) 2003-12-22 2005-07-14 Johns Hopkins University Boronic acid aryl analogs
WO2005097820A1 (en) 2004-04-06 2005-10-20 Korea Research Institute Of Bioscience And Biotechnology Peptides for inhibiting mdm2 function
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
WO2005110996A1 (en) 2004-05-18 2005-11-24 F.Hoffmann-La Roche Ag Novel cis-imidazolines
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
UA91027C2 (ru) 2004-09-22 2010-06-25 Янссен Фармацевтика Н.В. ИНГИБИТОРЫ ВЗАИМОДЕЙСТВИЯ МЕЖДУ MDM2 И р53
EA014445B1 (ru) * 2005-02-22 2010-12-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Низкомолекулярные ингибиторы mdm2 и их применения
SG176463A1 (en) * 2005-02-22 2011-12-29 Univ Michigan Small molecule inhibitors of mdm2 and uses thereof
US8236963B2 (en) 2005-05-24 2012-08-07 Merck Serono Sa Tricyclic spiro derivatives as CRTH2 modulators
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
US7495007B2 (en) 2006-03-13 2009-02-24 Hoffmann-La Roche Inc. Spiroindolinone derivatives
CN101400680B (zh) * 2006-03-13 2012-04-25 霍夫曼-拉罗奇有限公司 螺吲哚满酮衍生物
JP5385125B2 (ja) 2006-03-22 2014-01-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ＭＤＭ２とｐ５３の間の相互作用の阻害剤
NZ575193A (en) 2006-08-30 2011-12-22 Unversity Of Michigan Small molecule inhibitors of MDM2 comprising a spiropyrrolidine
US7737174B2 (en) * 2006-08-30 2010-06-15 The Regents Of The University Of Michigan Indole inhibitors of MDM2 and the uses thereof
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
US8002528B2 (en) * 2006-09-18 2011-08-23 Emerson Climate Technologies, Inc. Compressor assembly having vibration attenuating structure
DE602007006519D1 (de) 2006-09-21 2010-06-24 Hoffmann La Roche Oxindolderivate als antikrebsmittel
US7638548B2 (en) 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
KR20090090383A (ko) 2006-12-14 2009-08-25 다이이찌 산쿄 가부시키가이샤 이미다조티아졸 유도체
WO2008106507A2 (en) 2007-02-27 2008-09-04 University Of South Florida Mdm2/mdmx inhibitor peptide
CA2682483A1 (en) 2007-03-29 2008-10-09 Novartis Ag 3-imidazolyl-indoles for the treatment of proliferative diseases
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2008130614A2 (en) 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Selective and dual-action p53/mdm2/mdm4 antagonists
US7553833B2 (en) 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
US7834179B2 (en) 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
ATE547415T1 (de) 2007-09-21 2012-03-15 Janssen Pharmaceutica Nv Inhibitoren der wechselwirkung zwischen mdm2 und p53
RU2360914C1 (ru) * 2007-10-31 2009-07-10 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" Анальгетическое средство
CZ301561B6 (cs) 2007-12-04 2010-04-14 Výzkumný ústav živocišné výroby, v. v. i. Prostredek pro prevenci a potlacování kokcidióz
US8134001B2 (en) 2007-12-14 2012-03-13 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
US7723372B2 (en) 2008-03-19 2010-05-25 Hoffman-La Roche Inc. Spiroindolinone derivatives
EP2298778A4 (en) 2008-06-12 2011-10-05 Daiichi Sankyo Co Ltd IMIDAZOTHIAZOL DERIVATIVE WITH 4,7-DIAZASPIRO [2.5] OCTAN RING STRUCTURE
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
US7928233B2 (en) 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
UA107814C2 (uk) * 2009-11-12 2015-02-25 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Спірооксіндольні антагоністи мdм2
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
WO2011106650A2 (en) 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
RU2012147597A (ru) 2010-04-09 2014-05-20 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Биомаркеры для ингибиторов mdm2, использующиеся для лечения заболевания
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
US20120046306A1 (en) 2010-08-18 2012-02-23 David Joseph Bartkovitz Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
US20120071499A1 (en) 2010-09-20 2012-03-22 Xin-Jie Chu Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
EP2638046A4 (en) 2010-11-12 2014-06-25 Univ Michigan SPIRO-OXINDOLES ANTAGONISTS OF MDM2
BR112013028983A2 (pt) 2011-05-11 2017-02-07 Sanofi Sa antagonistas mdm2 espiro-oxindol

Also Published As

Publication number Publication date
GT201200147A (es) 2014-08-26
AR079026A1 (es) 2011-12-21
NZ600430A (en) 2014-06-27
CN104876938A (zh) 2015-09-02
RU2553269C2 (ru) 2015-06-10
CN102712650B (zh) 2015-05-20
US8877796B2 (en) 2014-11-04
CA2780547C (en) 2015-02-03
DOP2012000131A (es) 2012-09-30
CR20120313A (es) 2012-07-24
US8518984B2 (en) 2013-08-27
US9079913B2 (en) 2015-07-14
EP2499145A2 (en) 2012-09-19
MA33815B1 (fr) 2012-12-03
KR20120099462A (ko) 2012-09-10
TW201129570A (en) 2011-09-01
UY33029A (es) 2011-06-30
ECSP12011943A (es) 2012-07-31
CO6501131A2 (es) 2012-08-15
US20130296303A1 (en) 2013-11-07
EP2499145B1 (en) 2016-01-27
IL219706A (en) 2016-07-31
UA107814C2 (uk) 2015-02-25
ZA201203323B (en) 2013-01-30
MX2012005507A (es) 2012-07-03
AU2010319595B2 (en) 2015-09-17
US20140378680A1 (en) 2014-12-25
WO2011060049A2 (en) 2011-05-19
CN102712650A (zh) 2012-10-03
IL219706A0 (en) 2012-07-31
RU2012124056A (ru) 2013-12-20
WO2011060049A3 (en) 2011-10-20
TWI508967B (zh) 2015-11-21
AU2010319595A1 (en) 2012-06-28
CA2780547A1 (en) 2011-05-19
EP2499145A4 (en) 2013-07-10
US20110112052A1 (en) 2011-05-12
NI201200083A (es) 2012-10-29
TN2012000161A1 (en) 2013-12-12
CL2012001250A1 (es) 2012-11-30
JP2013510860A (ja) 2013-03-28
BR112012011317A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
PE20121282A1 (es) Antagonistas de espiro-oxindol de mdm2
PE20171329A1 (es) Agentes inmunorreguladores
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
PE20120635A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
AR054482A1 (es) Derivados de azetidinona para el tratamiento de hiperlipidemias
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
PE20110153A1 (es) Derivados de piridazina como inhibidores de smo
PE20141075A1 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20121479A1 (es) Inhibidores del virus de la hepatitis c
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
PE20110547A1 (es) Compuestos de isoindolina con actividad anticancerigena
PE20091371A1 (es) Inhibidores de hsp90
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20130647A1 (es) Indoles
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
CO5611147A2 (es) Derivados de nicotinamida utiles como inhibidores p38
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace
AR066781A1 (es) Compuestos de imidazopirimidina inhibidores de cinasa
HK1110868A1 (en) Heterocyclic compounds as ccr2b antagonists

Legal Events

Date Code Title Description
FC Refusal